Therapeutic Responses of Plasmodium vivax Malaria to Chloroquine and Primaquine Treatment in Northeastern Myanmar

摘要: Chloroquine-primaquine (CQ-PQ) continues to be the frontline therapy for radical cure of Plasmodium vivax malaria. Emergence CQ-resistant (CQR) P. parasites requires a shift artemisinin combination therapies (ACTs), which imposes significant financial, logistical, and safety burden. Monitoring therapeutic efficacy CQ is thus important. Here, we evaluated CQ-PQ malaria in northeast Myanmar. We recruited 587 patients with monoinfection attending local clinics during 2012 2013. These received three daily doses at total dose 24 mg base/kg body weight an 8-day PQ treatment (0.375 mg/kg/day) commencing same time as first dose. Of 401 who finished 28-day follow-up, cumulative incidence recurrent parasitemia was 5.20% (95% confidence interval [CI], 3.04% 7.36%). Among 361 (61%) finishing 42-day blood-stage infection reached 7.98% CI, 10.76%). The risk gametocyte carriage days 28 42 2.21% 0.78% 3.64%) 3.93% 1.94% 5.92%), respectively. Interestingly, all 15 gametocytemia, this associated concurrent asexual stages. Genotyping merozoite surface protein 3α gene locus from 12 within revealed that 10 these were genotype day 0, suggesting recrudescence or relapse. Similar studies 70 area 2007 showed no parasitemias days. sensitivity chloroquine northeastern Myanmar may deteriorating.